No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-Resistant Chronic Hepatitis B

      Background & Aims

      A recent study compared the efficacy of tenofovir disoproxil fumarate (TDF) vs the combination of emtricitabine and TDF (FTC/TDF) in patients with lamivudine-resistant chronic hepatitis B who were treated for as long as 96 weeks. We report findings from resistance analyses conducted for this study.


      Two hundred eighty patients with chronic hepatitis B virus (HBV) infection and lamivudine resistance (confirmed by INNO-LiPA Multi-DR) were randomly assigned (1:1) to groups treated with TDF or FTC/TDF. The HBV reverse transcriptase domain from the polymerase gene from all patients was sequenced at baseline and from 18 viremic patients at week 96 or early discontinuation.


      At screening for the efficacy study, 99% of patients were found to have lamivudine resistance. Prior exposure to entecavir or entecavir resistance was observed in 12% of patients, and 22% of patients had been previously exposed to adefovir; 1.8% were resistant to adefovir. Only 18 patients (6.4%) qualified for sequence analysis, including 1 patient who experienced virologic breakthrough and 17 with persistent viremia. Six of these patients did not have any sequence changes from baseline in HBV reverse transcriptase (33%), and sequence analysis could not be performed for 5 patients (28%). In 2 patients who qualified for phenotypic analysis (1 given TDF and 1 given FTC/TDF), no resistance to TDF was observed. Neither previous treatment exposure nor resistance to entecavir or adefovir affected viral kinetics. However, the mean baseline level of HBV DNA was significantly higher in viremic patients than in patients with viral suppression by week 96 (7.28 log10 IU/mL vs 5.62 log10 IU/mL; P = .0003).


      No resistance to TDF was detected through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Prior treatment or resistance to entecavir or adefovir did not affect viral kinetics through 96 weeks. No additional benefit was observed with the addition of emtricitabine vs TDF monotherapy. number: NCT00737568


      Abbreviations used in this paper:

      ADV (adefovir), ADV-R (adefovir resistance), CHB (chronic hepatitis B), ETV (entecavir), ETV-R (entecavir resistance), FTC (emtricitabine), HBV (hepatitis B virus), LAM (lamivudine), LAM-R (lamivudine resistantance), pol/RT (HBV polymerase/reverse transcriptase), TDF (tenofovir disoproxil fumarate)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Pan C.Q.
        • Hu K.Q.
        • Tsai N.
        Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
        Antivir Ther. 2013; 18: 841-852
        • Zoulim F.
        • Locarnini S.
        Management of treatment failure in chronic hepatitis B.
        J Hepatol. 2012; 56: S112-S122
        • Lok A.S.F.
        • Lai C.-L.
        • Leung N.
        • et al.
        Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
        Gastroenterology. 2003; 125: 1714-1722
        • Fasano M.
        • Lampertico P.
        • Marzano A.
        • et al.
        HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years.
        J Hepatol. 2012; 56: 1254-1258
        • Liaw Y.-F.
        • Sung J.J.Y.
        • Chow W.C.
        • et al.
        Lamivudine for patients with chronic hepatitis B and advanced liver disease.
        N Engl J Med. 2004; 351: 1521-1531
        • European Association for the Study of the Liver (EASL)
        EASL clinical practice guidelines: management of chronic hepatitis B virus infection.
        J Hepatology. 2012; 57 ([published version]): 167-185
        • Ghany M.G.
        • Strader D.B.
        • Thomas D.L.
        • et al.
        Diagnosis, management, and treatment of hepatitis C: an update.
        Hepatology. 2009; 49: 1335-1374
        • Liaw Y.F.
        • Kao J.H.
        • Piratvisuth T.
        • et al.
        Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.
        Hepatol Int. 2012; 6: 531-561
        • Lok A.S.
        • McMahon B.J.
        Chronic hepatitis B: update 2009.
        Hepatology. 2009; 50: 1-36
        • Lampertico P.
        • Vigano M.
        • Manenti E.
        • et al.
        Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
        Hepatology. 2005; 42: 1414-1419
        • Lampertico P.
        • Vigano M.
        • Manenti E.
        • et al.
        Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
        Gastroenterology. 2007; 133: 1445-1451
        • Fung S.K.
        • Chae H.B.
        • Fontana R.J.
        • et al.
        Virologic response and resistance to adefovir in patients with chronic hepatitis B.
        J Hepatol. 2006; 44: 283-290
        • Ha M.
        • Zhang G.
        • Diao S.
        • et al.
        Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
        Intern Med. 2012; 51: 1509-1515
        • Tenney D.J.
        • Rose R.E.
        • Baldick C.J.
        • et al.
        Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy.
        Hepatology. 2009; 49: 1503-1514
        • Marcellin P.
        • Heathcote E.
        • Buti M.
        • et al.
        Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
        N Engl J Med. 2008; 359: 2442-2455
        • Kitrinos K.M.
        • Corsa A.
        • Liu Y.
        • et al.
        No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B.
        Hepatology. 2014; 59: 434-442
        • Delaney IV, W.E.
        • Ray A.S.
        • Yang H.
        • et al.
        Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.
        Antimicrob Agents Chemother. 2006; 50: 2471-2477
        • Lada O.
        • Benhamou Y.
        • Cahour A.
        • et al.
        In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
        Antiviral Therapy. 2004; 9: 353-363
        • Hann H.W.
        • Chae H.B.
        • Dunn S.R.
        Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV).
        Hepatol Int. 2008; 2: 244-249
        • Kuo A.
        • Dienstag J.L.
        • Chung R.T.
        Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.
        Clin Gastroenterol Hepatol. 2004; 2: 266-272
        • van Bommel F.
        • de Man R.A.
        • Wedemeyer H.
        • et al.
        Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
        Hepatology. 2010; 51: 73-80
        • Patterson S.J.
        • George J.
        • Strasser S.I.
        • et al.
        Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
        Gut. 2011; 60: 247-254
        • Fung S.
        • Kwan P.
        • Fabri M.
        • et al.
        Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
        Gastroenterology. 2014; 146: 980-988
        • Murray K.F.
        • Szenborn L.
        • Wysocki J.
        • et al.
        Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.
        Hepatology. 2012; 56: 2018-2026
        • Zhu Y.
        • Curtis M.
        • Borroto-Esoda K.
        HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays.
        J Virol Methods. 2011; 173: 340-346
        • Yuen M.F.
        • Lai C.L.
        Treatment of chronic hepatitis B: evolution over two decades.
        J Gastroenterol Hepatol. 2011; 26: 138-143
        • Marcellin P.
        • Gane E.
        • Buti M.
        • et al.
        Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
        Lancet. 2013; 381: 468-475
        • Tenney D.J.
        • Rose R.E.
        • Baldick C.J.
        • et al.
        Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
        Antimicrob Agents Chemother. 2007; 51: 902-911
        • Berg T.
        • Zoulim F.
        • Moeller B.
        • et al.
        Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients.
        J Hepatol. 2014; 60: 715-722
        • Gordon S.C.
        • Krastev Z.
        • Horban A.
        • et al.
        Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.
        Hepatology. 2013; 58: 505-513
        • Lok A.S.
        • Trinh H.
        • Carosi G.
        • et al.
        Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B.
        Gastroenterology. 2012; 143: 619-628
        • Wong G.L.
        • Chan H.L.
        • Chan H.Y.
        • et al.
        Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
        Gastroenterology. 2013; 144: 933-944
        • Zoutendijk R.
        • Reijnders J.G.
        • Zoulim F.
        • et al.
        Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.
        Gut. 2013; 62: 760-765